Posted: February 2017 Gerard A. Silvestri is the 79th President of the American College of Chest Physicians, effective November 2017. Dr. Silvestri is Hillenbrand Professor of Thoracic Oncology and Vice-Chair of […] Read more
John C. Ruckdeschel, MD
Posted: February 2017 John C. Ruckdeschel has been appointed Director, University of Mississippi Medical Center Cancer Institute, Jackson, MS. Previous to this appointment, Dr. Ruckdeschel was Medical Director, Oncology Program and […] Read more
Ugo Pastorino, MD
Posted: February 2017 Ugo Pastorino received the Joseph W. Cullen/Early Detection Award, which is given to to a lung cancer specialist in recognition of his or her scientific achievements in research […] Read more
Keunchil Park, MD, PhD
Posted: February 2017 Keunchil Park received the 2016 IASLC Merit Award, which is given to lung cancer specialists who have made extraordinary contributions to the IASLC’s development. Dr. Park is Professor, […] Read more
Dr. Benjamin Levy, MD
Posted: February 2017 Dr. Benjamin Levy has been appointed Clinical Director, Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital and Medical Director of the Thoracic Oncology Program in Washington, […] Read more
Posted: February 2017 Keith Kerr received the 2016 IASLC Mary J. Matthews Pathology/ Translational Research Award, which is given to a scientist for lifetime scientific achievements in pathology/translational research of thoracic […] Read more
Roy S. Herbst, MD, PhD
Posted: February 2017 Roy S. Herbst received the 2016 IASLC Paul A. Bunn, Jr. Scientific Award, which is given to an oncologist who has made outstanding scientific contributions to thoracic cancer […] Read more
Peter Hammerman, MD, PhD
Posted: February 2017 Peter Hammerman has been appointed Global Head, Oncology Translational Research at Novartis Institutes for BioMedical Research (NIBR). Previous to this appointment, Dr. Hammerman was a Medical Oncologist and […] Read more
Posted: February 2017 BY Erik J. Maclaren, PhD Breakthrough Therapy Designation and Mechanisms of Expedited Review The U.S. Food and Drug Administration (FDA) is responsible for reviewing the evidence of […] Read more
Posted: February 2017 By Fred R. Hirsch, MD, PhD In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In recognition of the potential […] Read more